000			02131 a2200589 4500
005			20250516071907.0
264		0	_c20120618
008			201206s 0 0 eng d
022			_a1538-8514
024	7		_a10.1158/1535-7163.MCT-11-0406 _2doi
040			_aNLM _beng _cNLM
100	1		_aMontano, Ryan
245	0	0	_aPreclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. _h[electronic resource]
260			_bMolecular cancer therapeutics _cFeb 2012
300			_a427-38 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural
650	0	4	_aAntimetabolites _xpharmacology
650	0	4	_aAntineoplastic Agents _xpharmacology
650	0	4	_aBlotting, Western
650	0	4	_aCamptothecin _xanalogs & derivatives
650	0	4	_aCell Cycle Checkpoints _xdrug effects
650	0	4	_aCell Line
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Proliferation _xdrug effects
650	0	4	_aCell Survival _xdrug effects
650	0	4	_aCheckpoint Kinase 1
650	0	4	_aCytarabine _xpharmacology
650	0	4	_aDNA Breaks, Double-Stranded _xdrug effects
650	0	4	_aDNA Damage
650	0	4	_aDeoxycytidine _xanalogs & derivatives
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Screening Assays, Antitumor
650	0	4	_aDrug Synergism
650	0	4	_aFlow Cytometry
650	0	4	_aHumans
650	0	4	_aHydroxyurea _xpharmacology
650	0	4	_aIrinotecan
650	0	4	_aMolecular Structure
650	0	4	_aPhosphorylation _xdrug effects
650	0	4	_aProtein Kinase Inhibitors _xchemistry
650	0	4	_aProtein Kinases _xmetabolism
650	0	4	_aPyrazoles _xchemistry
650	0	4	_aPyrimidines _xchemistry
650	0	4	_aStaurosporine _xanalogs & derivatives
650	0	4	_aGemcitabine
700	1		_aChung, Injae
700	1		_aGarner, Kristen M
700	1		_aParry, David
700	1		_aEastman, Alan
773	0		_tMolecular cancer therapeutics _gvol. 11 _gno. 2 _gp. 427-38
856	4	0	_uhttps://doi.org/10.1158/1535-7163.MCT-11-0406 _zAvailable from publisher's website
999			_c21423111 _d21423111